The Longevity Research Stack: NAD+ + SS-31 + Ipamorelin Protocol

Research Disclaimer: All compounds described are sold exclusively for in-vitro and laboratory research use. Not for unsupervised use. This content does not constitute medical advice.

No single compound targets all hallmarks of aging — the multi-factorial nature of senescence means effective longevity research requires a multi-target approach. The NAD+ + SS-31 + ipamorelin stack addresses three mechanistically distinct aging processes: the decline in sirtuin activity (NAD+ precursors → SIRT1/SIRT3), the collapse of mitochondrial cristae architecture (SS-31 → cardiolipin stabilization), and GH/IGF-1 somatopause (ipamorelin → GHSR-1a → pulsatile GH restoration). This guide covers the rationale and research protocol for this combination.

Why Three Different Targets?#

Aging Hallmark 1 — NAD+ Decline / Sirtuin Dysfunction:

• With aging: CD38 nucleosidase activity increases → NAD+ consumed faster
• Result: SIRT1 (nuclear) and SIRT3 (mitochondrial) have less substrate → reduced activity
• Consequences: impaired DNA repair (PARP competition for NAD+), impaired autophagy, impaired mitochondrial biogenesis
• Intervention: NAD+ precursors (NMN/NR) → restore cellular NAD+ → reactivate sirtuins → multiple downstream benefits

Aging Hallmark 2 — Mitochondrial Dysfunction:

• Independently of NAD+ decline: cardiolipin oxidizes with aging → cristae architecture disrupts → ETC supercomplex disassembly → reduced OXPHOS efficiency
• This is a structural problem that NAD+ supplementation alone cannot fix
• Intervention: SS-31 → targets cardiolipin directly → preserves cristae → improves ETC efficiency without requiring new mitochondria

Aging Hallmark 3 — Somatopause / GH/IGF-1 Decline:

• GH pulse amplitude: ~50% lower in 60-year-olds vs. 20-year-olds
• IGF-1 declines proportionally → reduced mTOR signaling → reduced satellite cell activity → sarcopenia, reduced bone density, impaired tissue repair
• Intervention: ipamorelin → GHSR-1a → restores pulsatile GH → elevated IGF-1 → reverses somatopause features

Why combine all three: Each addresses a separate, non-overlapping mechanism. No redundancy; no receptor competition. The three pathways converge on common aging outcomes (body composition decline, reduced energy, impaired repair) but through distinct biology.

Research Protocol for the Longevity Stack#

Model: 24-month-old C57BL/6J mice (aged animal model; equivalent to ~65–70 year old human)

Study duration: 12–16 weeks (sufficient for body composition changes to become measurable in aged mice)

Groups (minimum design):

1. Vehicle (aged control)
2. NAD+ alone
3. SS-31 alone
4. Ipamorelin alone
5. NAD+ + SS-31 + Ipamorelin (full stack)
6. Young mice (positive reference, age 6–8 months)

The 6-group design allows assessment of individual vs. combined effects and comparison to young animal baseline.

Research Endpoints#

Body composition:

• DEXA at baseline, 8 weeks, endpoint: lean mass, fat mass, bone mineral density
• Grip strength (dynamometer): functional strength proxy

Mitochondrial function (primary for SS-31 + NAD+ arms):

• Seahorse XF assay on isolated mitochondria or permeabilized muscle fibers: OCR (basal, uncoupled, maximal), ATP production rate
• mtDNA:nDNA ratio (qPCR): mitochondrial content
• TMRM or JC-1 staining: membrane potential

NAD+ metabolomics:

• Tissue NAD+/NADH ratio: enzymatic cycling assay on liver, muscle, brain
• SIRT1 activity assay: deacetylase assay using acetyl-H3K9 substrate

GH/IGF-1 axis:

• Serum IGF-1 (ELISA): primary biomarker; measure monthly
• GH pulse sampling (serial blood, q20min × 3h): confirms pulsatile GH restoration

Cognitive and physical performance:

• Morris water maze: spatial memory
• Rotarod: balance and coordination
• Open field: locomotor activity

Research Use Only. JuicedPharma does not provide medical advice.

Published by JuicedPharma Research Team · October 2026 · Category: Research Protocols & Science